Statin use in CLL/SLL patients treated with ibrutinib reduced cancer-related death risk by 61% and improved survival outcomes. The study found no significant increase in severe side effects with ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

At a median duration of follow-up of 6.6 months, treatment with pirtobrutinib reduced the risk of progression or death by 42%. The Food and Drug Administration (FDA) has approved Jaypirca ® ...

(RTTNews) - Eli Lilly and Co. (LLY) announced that the FDA has expanded cancer med Jaypirca's approval to include treatment for adults with relapsed or refractory chronic lymphocytic leukemia or small ...

When Nathan was diagnosed with chronic lymphocytic leukemia (CLL) at just 45 years old, his world turned upside down overnight. As a military veteran and ER nurse, he was no stranger to facing ...

(WASHINGTON—April 23, 2025) — Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were taking cholesterol-lowering statin medications at the start of their cancer ...

Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...

Acalabrutinib in combination with venetoclax reduced the risk of disease progression or death by 35% compared with investigator’s choice of chemotherapy. The Food and Drug Administration (FDA) has ...

New data from SEQUOIA, to be reported in two oral presentations, underscore the benefits of BRUKINSA® as first-line treatment for patients with chronic lymphocytic leukemia (CLL) Promising early phase ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Matthew S. Davids, MD, said data from the BRUIN-313 trial supports front-line approval ...

Please provide your email address to receive an email when new articles are posted on . In the BRUIN CLL-313 trial, researchers compared pirtobrutinib (Jaypirca, Eli Lilly & Co.) vs. bendamustine plus ...

Time-limited venetoclax–obinutuzumab was the predominant first-line regimen, while continuous BTK inhibitor therapy remained nearly as common, and chemoimmunotherapy was rarely selected. Enrichment ...